Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Shares Outstanding (Weighted Average) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $15.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 6.17% to $15.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.5 million, a 6.17% increase, with the full-year FY2024 number at $14.8 million, up 25.62% from a year prior.
  • Shares Outstanding (Weighted Average) was $15.5 million for Q3 2025 at Inhibrx Biosciences, roughly flat from $15.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $15.5 million in Q3 2025 to a low of $10.9 million in Q2 2023.
  • A 3-year average of $13.8 million and a median of $14.4 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 29.49% in 2024, then grew 6.17% in 2025.
  • Inhibrx Biosciences' Shares Outstanding (Weighted Average) stood at $11.8 million in 2023, then grew by 25.62% to $14.8 million in 2024, then grew by 4.57% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Shares Outstanding (Weighted Average) are $15.5 million (Q3 2025), $15.5 million (Q2 2025), and $15.5 million (Q1 2025).